A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511561-10-00

Acronym

IOB-022/KN-D38

Enrollment

Registered

2024-02-12

Start date

2022-05-31

Completion date

2025-11-28

Last updated

2025-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC)

Brief summary

Overall objective response rate (ORR) according to RECIST v. 1.1

Detailed description

Progression-Free Survival (PFS) according to RECIST v. 1.1, Duration of response (DOR), Complete response rate (CRR), Disease control rate (DCR), Time to response (TTR), Safety

Interventions

DRUGIO102-IO103

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall objective response rate (ORR) according to RECIST v. 1.1	—

Secondary

Measure	Time frame
Progression-Free Survival (PFS) according to RECIST v. 1.1, Duration of response (DOR), Complete response rate (CRR), Disease control rate (DCR), Time to response (TTR), Safety	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026